Inventia Healthcare Recalled Generic Chlorthalidone Tablets
Pharmacies and health providers must remove 25-milligram bottles failing dissolution specifications from inventory.
Updated on Sept. 19, 2026 in Healthcare
Live Poll
Do you trust the quality and safety standards of generic medications produced by overseas manufacturers?
Inventia Healthcare Limited initiated a nationwide recall of 13,567 bottles of 25-milligram chlorthalidone tablets on Sept. 3, 2026. The FDA officially classified this as a Class II action on Sept. 17, 2026, citing failed dissolution specifications that could impact how the medication is absorbed.
Why it matters
Operators in the pharmacy and clinical supply chain must audit inventory to ensure compliance with the recall of these 100-count bottles. This failure to meet dissolution standards represents a significant quality control issue that requires immediate adherence to regulatory withdrawal protocols.
The recall involves 13,567 bottles of 25-milligram chlorthalidone, following a separate recall of 11,460 bottles in June. Whether further batches face similar dissolution issues remains unknown.
The players
Inventia Healthcare Limited
An India-based pharmaceutical manufacturer that produces generic medication for the global market.
FDA
The U.S. federal agency responsible for protecting public health by regulating the safety and efficacy of pharmaceuticals.
The details
The medication failed to meet established dissolution specifications, meaning the active ingredient may not absorb correctly in a patient's system. Inventia Healthcare Limited is currently managing the nationwide recall process. Inventory managers must cross-reference their current stock of 100-count bottles against the company's specified product codes to ensure the affected units are pulled from shelves and quarantined.
Timeline
June 2026: Inventia Healthcare Limited recalled 11,460 bottles of chlorthalidone.
Sept. 3, 2026: The current recall was formally initiated.
Sept. 17, 2026: The FDA classified the action as a Class II recall.
Market Landscape
This action follows the FDA's established Class II recall protocol, which triggers when a product may cause temporary or medically reversible adverse health consequences. The manufacturer's second recall in three months underscores the regulatory scrutiny facing generic drug makers managing dissolution consistency.
Pharmacies and healthcare operators should immediately verify existing inventory levels for the recalled 25-milligram bottles. Coordinate with your wholesaler or the manufacturer to confirm the specific lot numbers involved and to arrange for secure product disposal or return.
The takeaway
Manufacturing instability can lead to repeat quality failures, requiring operators to maintain strict oversight of generic supply partners. Review your procurement contracts to ensure they include clear indemnification and replacement terms in the event of mandatory FDA product withdrawals.
Further reading
For broader trends in pharmaceutical supply chain compliance, see the latest reports in Healthcare.
Source note: This article includes information reported by Theepochtimes.
Live Poll
Do you trust the quality and safety standards of generic medications produced by overseas manufacturers?
